AbbVie to acquire Allergan in transformative move

25 Jun 2019

Transaction will create a leading biopharmaceutical company with approximately $48 billion in combined 2019 revenue.

AbbVie and Allergan have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion.

AbbVie to acquire Allergan in transformative move

"This is a transformational transaction for both companies and achieves unique and complementary strategic objectives," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "The combination of AbbVie and Allergan increases our ability to continue to deliver on our mission to patients and shareholders. With our enhanced growth platform to fuel industry-leading growth, this strategy allows us to diversify AbbVie's business while sustaining our focus on innovative science and the advancement of our industry-leading pipeline well into the future."

Strategic Rationale

  • New growth platforms and leadership positions to diversify and expand revenue base: The combined company will consist of several attractive franchises with leadership positions across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care and virology. Allergan's product portfolio will be enhanced by AbbVie's commercial strength, expertise and international infrastructure.
  • Immediate scale and enhanced profitability for AbbVie's growth platform: AbbVie's enhanced growth platform, comprised of growing and durable franchises across highly-attractive therapeutic areas, is expected to grow at a high-single digit annual growth rate well into the next decade, from more than $30 billion in 2020.
  • Financially attractive with immediate EPS accretion: This transaction is expected to be 10% accretive to adjusted earnings per share over the first full year following the close of the transaction, with peak accretion of greater than 20%.1 ROIC is expected to exceed AbbVie's cost of capital within the first full year.
  • Significant cash flow generation: The success and scale of the combined commercial business ensures funding capacity and flexibility for simultaneous robust pipeline investment, debt reduction and capital return to shareholders. The combined companies generated $19 billion in operating cash flow in 2018.
  • "This acquisition creates compelling value for Allergan's stakeholders, including our customers, patients and shareholders. With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows, our combined company will have the opportunity to make even bigger contributions to global health than either can alone," said Brent Saunders, chairman and chief executive officer, Allergan. "Our fast-growing therapeutic areas, including our world-class medical aesthetics, eye care, CNS and gastrointestinal businesses, will enhance AbbVie's strong growth platform and create substantial value for shareholders of both companies."

    Read More

    Related news

    Eisai collaborates with University of Dundee on cancer drug discovery

    Eisai collaborates with University of Dundee on cancer drug discovery

    10 Jul 2019

    It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

    Read more 
    Onyx Scientific makes strategic investment in commercial API licence

    Onyx Scientific makes strategic investment in commercial API licence

    10 Jul 2019

    Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

    Read more 
    I Holland to share the science behind tool maintenance

    I Holland to share the science behind tool maintenance

    9 Jul 2019

    Proper maintenance - rather than replacement - of compression tooling will improve profitability.

    Read more 
    Catalent extends global commercial spray drying capabilities in Europe

    Catalent extends global commercial spray drying capabilities in Europe

    9 Jul 2019

    Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

    Read more 
    Operations commence at Wasdell Group’s EU headquarters

    Operations commence at Wasdell Group’s EU headquarters

    8 Jul 2019

    The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.

    Read more 
    Porvair Sciences launches first Drosophila ChIP kits

    Porvair Sciences launches first Drosophila ChIP kits

    4 Jul 2019

    Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.

    Read more 
    Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

    Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

    3 Jul 2019

    Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.

    Read more 
    Fresh data on protein interactions in Alzheimer’s disease

    Fresh data on protein interactions in Alzheimer’s disease

    2 Jul 2019

    Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

    Read more 
    Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

    Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

    2 Jul 2019

    The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.

    Read more 
    Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

    Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

    1 Jul 2019

    Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.

    Read more